Biomedical subjects

M Izuo

Publications and source records attributed to M Izuo.

At least 91 records · Page 5Linked to original sources

PubMed1986

[Evaluation of a tumor-associated antigen CA 15-3 in the sera of patients with breast cancer].

Serum levels of CA 15-3 were determined in normal women and patients with breast cancer and other diseases. The serum concentration of normal subjects was 9.8 +/- 4.4 units/ml (mean +/- S.D., n = 97). The patients with primary and recurrent breast cancer had significantly higher levels of CA 15-3, their values being 23.1 +/- 59.6 (n = 47) and 127.6 +/- 179.7 (n = 32) units/ml, respectively. When the value of 20 units/ml was used as the cutoff for the normal value, the positive rates were 4%, 26% and 75% in normal women and breast cancer patients primary and recurrent, respectively. No increased levels were found in the sera of patients with benign breast diseases or with gastrointestinal, thyroid, lung and other cancers. The elevated levels of CA 15-3 decreased after successful therapy both in primary and recurrent breast cancer patients, while there was no change in nonresponders. The measurement of serum CA 15-3 would be useful for monitoring the therapy and for detection of the recurrence of breast cancer.

Adolescent↗

PubMed1986

[Phase II study of epirubicin on breast cancer: a cooperative group study].

A phase II multicenter clinical study of epirubicin, a new anthracycline anticancer agent, was carried out in 46 patients with advanced breast cancer. The treatment schedule consisted of either 60 mg/m2 every three weeks or 40 to 50 mg/m2 on day 1 and day 8 every four weeks. Objective responses were observed in 23.7% of 38 evaluable patients (1 CR and 8 PR). Response rates according to previous chemotherapy were 50.0% (4/8) in previously non-treated patients and 36.4% (4/11) in patients previously treated with non-anthracyclines. The major adverse effect was bone-marrow suppression; leukopenia was observed in 82.1% of patients, anemia in 53.8% and thrombocytopenia in 20.0%. Other toxicities frequently observed were anorexia (55.0%), nausea-vomiting (55.0%) and alopecia (66.7%), but these seemed to be milder than those produced by doxorubicin.

Adult↗

PubMed1986

[A prospective randomized trial comparing epirubicin and doxorubicin in advanced or recurrent breast cancer].

A randomized clinical trial comparing epirubicin (EPI) and doxorubicin (DX) was conducted in patients with advanced or recurrent breast cancer. The dosage employed was 60 mg/m2 for EPI and 40 mg/m2 for DX at intervals of three weeks. There were 40 patients entered into the EPI group and 39 into the DX group. Background factors analysed were well balanced in both groups. The response rate was 56.3% in the EPI group (5 CR and 13 PR among 32 evaluable patients), and 35.5% in the DX group (1 CR and 10 PR among 31 evaluable patients), and the difference between both groups was statistically significant (P less than 0.05) by U-test. The response duration and time to response showed no significant difference between both groups. The incidences and grades of hematologic and non-hematologic toxicities were nearly identical. We conclude that EPI is a useful drug for the treatment of advanced breast cancer.

Adult↗

PubMed1986

[Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].

Using the Su-PS skin test, an attempt was made to evaluate whether or not this reaction could become a useful immune parameter in patients with gastrointestinal cancer. The conclusions were as follows: Late-stage patients with gastric cancer showed a weak response in the Su-PS skin test when examined preoperatively. The skin reaction to Su-PS was shown to become stronger than in the PPD and PHA test when patients received OK-432 treatment. Patients with advanced cancer having longer survival (more than 7 months) showed stronger response in the Su-PS skin test that patients having short survival (less than 6 months). It was suggested that the Su-PS skin test was useful for evaluating the immune response to OK-432 treatment.

Biological Products↗

PubMed1986

[Phase II study of THP (2''R)-4'-0-tetrahydropyranyladriamycin) in breast cancer].

In a phase II study of THP, fifty-six patients with advanced or recurrent breast cancer were evaluated, and a response rate of 23.2% including 1.8% with complete response and 21.4% with partial response, was obtained. Response rates of THP varied according to the location of metastasis and the highest rate was shown to be 38.5% in patients with soft tissue metastasis. The median dose for inducing response was 100 mg with a range from 60 mg to 160 mg. Toxicities such as leukopenia and gastrointestinal disorders were observed during THP treatment. The favorable response to THP was close to that of adriamycin, but it was noteworthy that a lower frequency of alopecia occurred.

Adult↗

PubMed1985

A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer.

A randomized controlled trial was performed to compare the therapeutic results of oral high-dose medroxyprogesterone acetate (HD-MPA) versus mepitiostane (MS) in the treatment of postmenopausal breast cancer. MPA was given at three doses of 400 mg orally daily to 47 patients and produced objective responses in 19 cases (40.4%). An objective response was seen in 14 of the 40 control patients given MS at two doses of 10 mg orally daily (35.0%). Among patients with bone metastases, 6 of 19 (31.6%) for HD-MPA and 2 of 13 (15.4%) for MS showed objective responses. The other merits of HD-MPA suggested in the study were improvement in performance status, increase in appetite, and myeloprotective effect.

Adult↗

PubMed1985

[Comparative studies on immunological property of thyroglobulins obtained from the thyroid tumor and the adjacent tissue].

The immunological properties of thyroglobulins (Tg) of individual patients, obtained from a thyroid tumor and its adjacent tissue were compared, using conventional or monoclonal antibodies against human Tg. The thyroid tumors studied were non-functioning thyroid carcinomas and functioning thyroid adenomas. In contrast to non-functioning tumors, Tg from the functioning tumors was generally iodinated at a level close to that of normal tissue, and Tg from the tissue adjacent to the tumors had a very low iodine content. The conventional antiserum and monoclonal antibodies, B2F, seemed to recognize the conformation of Tg, while C6G showed a high affinity to Tg even when unfolded or denatured. In most cases, Tg isolated from the tissue adjacent to a tumor showed a higher affinity to antibodies than Tgs of the tumor tissue, as determined by the inhibitional effect of these Tgs against the binding of standard Tg and antibody. Furthermore, the Tg of the adjacent tissue was immunologically different in nature from the standard Tg obtained from a normal thyroid gland. From these results, Tgs of tumor and the adjacent tissue in individual patients were heterogeneous in immunological property, regardless of iodine content.

Adenocarcinoma↗

PubMed1985

[The immunochemical properties of thyroglobulin in human thyroid tumors in reaction to rabbit anti-human normal thyroglobulin-serum].

Interactions between antiserum (rabbit anti-human normal thyroglobulin-serum) and human thyroglobulin preparations (obtained from the tissues of the normal thyroid gland, thyroid adenoma, and carcinoma) were compared by inhibition effect with the binding between 131I-labeled standard thyroglobulin and antiserum, set up by a double antibody RIA. Thyroglobulins isolated from normal glands (designated as Nor-Tg) have a high affinity to the antiserum. In contrast, thyroglobulins in follicular adenoma or adenomatous goiter (designated as Ad-Tg) decrease the potency of the affinity to the antiserum. Furthermore, thyroglobulins in papillary or follicular carcinoma (designated as Ca-Tg) markedly decrease such a potency. With the t-test, the inhibition curves of Nor-Tgs are almost parallel to each other. Most of the inhibition curves of Ad-Tgs and Ca-Tgs are not parallel to the curve of Nor-Tg 1 (P-value for non-parallelism less than or equal to 0.05). Therefore, it seems that Tg preparations obtained from tumor tissue are heterogeneous in terms of specificity and/or affinity to antiserum, judging from the results of the non-parallel inhibition curves. The present results also show that the contribution of iodine content in Tg has little or no effect on the nature of Tg-immunogenicity.

Adenoma↗

PubMed1985

[An analysis of treatments of recurrent breast cancer in relation to the lesion].

One hundred fifty-four patients being treated for recurrent breast cancer were studied for response rates and prognosis according to first recurrent lesions in radiation, chemotherapy, hormone therapy and combined therapy groups. It was important to consider the sites of the recurrent lesions in the treatments. Although there was no significant difference in prognosis among the first recurrent therapy groups, the overall cumulative five-year survival rate of the patients who responded (to the initial treatment) was significantly better than that of those who did not. As for the treatment of recurrent breast cancer, it is important to consider hormone receptor, lesion and age and to choose the effective mode of treatment for the first (recurrence of the) disease.

Breast Neoplasms↗

PubMed1985

[Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].

A randomized controlled trial was made to compare the therapeutic result of oral high-dose medroxyprogesterone acetate (HD-MPA) versus mepitiostane (MS) in the treatment of postmenopausal breast cancer. MPA (1200 mg) was given p.o., b.i.d. to 47 patients and produced objective response in 19 of them (40.4%). Objective response was seen in 14 of the 40 control patients given MS p.o., b.i.d. (35.0%). Among patients with bone metastases, 6/19 (31.6%) for HD-MPA and 2/23 (15.4%) for MS showed objective response. The other merits of HD-MPA suggested in the study were improvement in performance status, anabolic effect and myeloprotective effect.

Administration, Oral↗

PubMed1985

[Present state of the multidisciplinary treatment of locoregionally advanced breast cancer].

Recent intensive combined chemotherapy regimen including adriamycin is very effective in objective regression in locoregional and distant metastatic lesions of breast cancer. This report analyses our results in treating stage III b and IV breast cancer patients by a series of treatment, namely, intensive induction therapy, subsequent mastectomy and radiotherapy, and maintenance systemic therapies such as chemical, hormonal and/or immunotherapy. And the results about similar combined treatment program in the recent reports are also discussed. This kind of multidisciplinary treatment for the patient with locoregionally advanced breast cancer (stage III b) can be expected to improve long-term results.

Antineoplastic Combined Chemotherapy Protocols↗

PubMed1985

[The relationship of breast cancer and thyroid diseases].

A relationship between breast cancer and thyroid diseases has been postulated for many years. Several studies have demonstrated an increased risk of breast carcinoma in patients with goiter, chronic thyroiditis (hypothyroidism) or thyroid supplement therapy itself, while others have shown either a slight, nonsignificant excess or none at all. In an overview of the literature, the results were inconclusive and rather controversial in each other. Apart from the thyroid disorders mentioned above, a relationship between thyroid cancer and breast cancer also has been suggested in the recent studies. This is rather probable as a fact, but common risk factors for the two cancers have not been clarified yet and remains in future problem.

Adenoma↗

PubMed1985

[Significance of CEA in gastric and colorectal cancer].

The determination of serum CEA (Sandwich method) and CEA staining (PAP method) of excised specimens were performed in patients with gastric or colorectal cancer, and the biological characteristics of each cancer and the factors to increase serum CEA were studied with the following results: As colonic cancer has strong CEA productivity, serum CEA can be useful for the detection of cancer, and especially effective for the postoperative observation. Gastric cancer has weak CEA productivity, and serum CEA is not so useful in the detection of cancer and the judgement of resectability. The CEA positive rate of tissue with CEA staining was 80% in gastric cancer, 100% in colonic cancer, and were nearly equal to the CEA positive rate of serum in the group of terminal stage. In the mode of CEA staining of cancerous cells, IV type was observed most frequently in gastric cancer, and I type in colonic cancer. Among the resected cases showing more than 7ng/ml serum CEA, differentiated type, lymph node metastasis (+), the degree of tissue staining with CEA staining, the mode of cell staining O or I type in gastric cancer and I type in colonic cancer were observed in common.

Aged↗

PubMed1985

[5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207].

FT-207 or UFT was administered preoperatively to 74 patients with gastric cancer. The 5-FU and FT-207 concentrations in the serum and various tissues were investigated. The 5-FU concentration in various tissues was higher than in the serum after the administration of FT-207 or UFT. Especially it showed that 5-FU concentration in tumor was highest in other normal tissues. The 5-FU concentration in the tumor for the UFT group was higher than for the FT-207 group. There was a significant difference between the UFT and FT-207 groups (P less than 0.05). Levamisole had no influence on the concentration of 5-FU.

Antineoplastic Combined Chemotherapy Protocols↗

PubMed1985

[Clinicopathological features of recurrent breast cancer].

Recurrence of breast cancer is classified into three categories, namely local (chest wall) recurrence, recurrence in regional lymph nodes, and distant metastasis. In an analysis of 77 recurrent cases out of 385 breast cancer cases managed by us from 1962 to 1973, recurrence of the former two categories occurred early, mostly within three years, but distant metastatic disease occurred in later years. With regard to staging and the time of recurrence, it was observed in general that the earlier the initial stage of disease, the longer the time period until the presence of detectable recurrence. In addition, as to local recurrence and distant metastases in various sites, the following aspects were reviewed and discussed; incidence, mechanisms of recurrence, characteristics of the recurrent disease.

Bone Neoplasms↗

PubMed1985

[Clinico-pathological studies of non-palpable breast lesions with mammographically detected microcalcifications].

Fourty-two patients with suspected non-palpable cancer of the breast due to microcalcifications detected by mammography were studied. Histologically, carcinoma was found in 17 cases (40.5%) and benign lesions in 25 cases (32 foci) at biopsy or operation. Eight cases of these carcinomas were noninvasive and seven were microinvasive. Axillary metastasis was present in only one case. Sites of calcifications were confined to the area of carcinoma in 12 patients; both within a carcinoma and adjacent benign lesions in 3; only within the adjacent benign diseases in two. The features of microcalcification was not always useful to differentiate accurately the benign from the malignant. Therefore, local excision is essential to ensure histological diagnosis in the non-palpable breast lesions with microcalcification.

Adult↗

PubMed1985

[Concurrent medullary carcinoma adjacent to papillary carcinoma of the thyroid--a clinicopathological and electron microscopic study].

This paper describes an extremely rare case of the simultaneous occurrence of medullary and papillary thyroid carcinoma. A 31-year-old woman had two different coexistent tumors, i.e., medullary carcinoma (1.2 X 1.5 cm) adjacent to papillary carcinoma (2 X 1.8 cm) in the right lobe. The two different tumor cells revealed the characteristic features of each on the microscopic, histochemical and ultrastructural findings. Therefore, they must be derived from different origins. One lymph node contains metastases of mixed medullary and papillary carcinoma. Such an unusual case of concurrent medullary and papillary carcinoma seems to be interesting as to the histogenesis.

Adult↗

PubMed1984

Histochemical demonstration of endogenous estrogen in breast carcinomas: biochemical and clinical correlation.

In a study of 277 patients with breast carcinomas, the PAP immunoperoxidase method for demonstrating endogenous estrogen was correlated with the sucrose density gradient (SDG) assay and with histologic and clinical features. The results from the PAP method and SDG assay agreed in 59 of 84 patients (82.1%) on whom both methods were performed. Histologically, the PAP method was positive in 7 of 7 patients with non-invasive carcinomas, in 164 of 233 patients (70.4%) with common invasive ductal carcinoma, and in 21 of 22 of those with special histological types of of invasive carcinomas not including Paget's disease, medullary or apocrine carcinoma, where only 5 of 14 were positive. Clinically, 15 of 18 patients with positive endogenous estrogen showed a response to endocrine therapy as opposed to 1 of 9 patients with a negative endogenous estrogen. The mean survival was 31.2 and 15.6 months, respectively for patients with positive and negative endogenous estrogen. Remission for longer than 2 years was seen more often in patients with positive endogenous estrogen. These results suggest a clinical utility of the present PAP method which, therefore, deserves a further trial as an alternative to histochemical methods aiming at the estrogen receptors.

Breast Neoplasms↗